High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol
Open Access
- 1 September 2010
- journal article
- research article
- Published by Elsevier BV in Journal of Lipid Research
- Vol. 51 (9), 2714-2721
- https://doi.org/10.1194/jlr.m008144
Abstract
No abstract availableKeywords
This publication has 44 references indexed in Scilit:
- Strong induction of PCSK9 gene expression through HNF1α and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamstersJournal of Lipid Research, 2010
- Serum Proprotein Convertase Subtilisin Kexin Type 9 Is Correlated Directly with Serum LDL CholesterolClinical Chemistry, 2007
- Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activityBiochemical Journal, 2007
- Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosisJournal of Lipid Research, 2007
- Catalytic Activity Is Not Required for Secreted PCSK9 to Reduce Low Density Lipoprotein Receptors in HepG2 CellsPublished by Elsevier BV ,2007
- Binding of Proprotein Convertase Subtilisin/Kexin Type 9 to Epidermal Growth Factor-like Repeat A of Low Density Lipoprotein Receptor Decreases Receptor Recycling and Increases DegradationPublished by Elsevier BV ,2007
- Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic miceJournal of Lipid Research, 2007
- A Novel Loss of Function Mutation of PCSK9 Gene in White Subjects With Low-Plasma Low-Density Lipoprotein CholesterolArteriosclerosis, Thrombosis, and Vascular Biology, 2007
- Molecular biology of PCSK9: its role in LDL metabolismTrends in Biochemical Sciences, 2007
- Sequence Variations inPCSK9,Low LDL, and Protection against Coronary Heart DiseaseThe New England Journal of Medicine, 2006